002693.SHE Hainan Shuangcheng Pharmaceut
- Market cap
- CNY 3.15B
- P/E
- 69.0x
- P/B
- 7.44x
- ROE
- 6.9%
- Dividend yield
- 0.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002693.SHE undervalued?
Graham numberThe Graham number of Hainan Shuangcheng Pharmaceut cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hainan Shuangcheng Pharmaceut fundamental analysis
No fundamental analysis for Hainan Shuangcheng Pharmaceut yet.
Hainan Shuangcheng Pharmaceut stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pregabalin capsule; and Memantine Hydrochloride tablets and Pioglitazone tablets US…
Full company profileHainan Shuangcheng Pharmaceut financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hainan Shuangcheng Pharmaceut annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 145M | 247M | 337M | 347M | 269M | 320M | 275M | 236M | 174M | 277M | 256M |
| Gross Profit | 72.4M | 148M | 210M | 248M | 204M | 233M | 180M | 154M | 89.8M | 152M | 135M |
| Operating Income | -388M | 868K | -90.2M | 7.89M | -78.8M | -38.5M | -9.01M | -73.2M | -106M | 24.1M | 37.3M |
| EBITDA | -341M | 63.1M | -19.7M | 79.8M | -11.3M | 23.0M | 59.8M | -10.7M | -44.6M | 70.8M | 33.1M |
| Net Income | -388M | 6.31M | -69.5M | 24.7M | -53.3M | -20.3M | 9.01M | -50.7M | -78.3M | 19.0M | 29.9M |
| EPS | -0.96 | 0.02 | -0.17 | 0.06 | -0.13 | -0.05 | 0.02 | -0.12 | -0.19 | 0.05 | 0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 1.17B | 1.38B | 1.12B | 951M | 908M | 855M | 911M | 803M | 784M | 826M | 829M |
| Total Liabilities | 612M | 615M | 451M | 273M | 309M | 288M | 330M | 286M | 372M | 405M | 390M |
| Shareholders' Equity | 553M | 591M | 522M | 546M | 493M | 482M | 514M | 471M | 393M | 412M | 435M |
| Cash & Short-term Investments | 25.0M | 31.7M | 68.1M | 95.5M | 100M | 77.0M | 146M | 31.9M | 45.1M | 59.1M | 48.8M |
| Total Debt | 487M | 367M | 306M | 167M | 223M | 167M | 205M | 135M | 185M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 38.6M | -22.5M | 46.8M | 66.6M | -10.5M | 23.6M | 25.2M | 11.6M | -40.8M | 60.9M | - |
| Capital Expenditure | 183M | 70.2M | 22.4M | 51.5M | 51.6M | 31.6M | 33.0M | 49.2M | 24.9M | 43.3M | 40.8M |
| Free Cash Flow | -144M | -92.7M | 24.5M | 15.1M | -62.1M | -8.09M | -7.77M | -37.6M | -65.7M | 17.7M | 20.5M |
| Ratios | |||||||||||
| ROE | -70.2% | 1.1% | -13.3% | 4.5% | -10.8% | -4.2% | 1.8% | -10.8% | -19.9% | 4.6% | 6.9% |
| ROA | -33.3% | 0.5% | -6.2% | 2.6% | -5.9% | -2.4% | 1.0% | -6.3% | -10.0% | 2.3% | 3.6% |
| Net Profit Margin | -267.6% | 2.6% | -20.6% | 7.1% | -19.8% | -6.3% | 3.3% | -21.5% | -44.9% | 6.9% | 11.7% |
| Debt to Equity | 0.88x | 0.62x | 0.59x | 0.31x | 0.45x | 0.35x | 0.40x | 0.29x | 0.47x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hainan Shuangcheng Pharmaceut dividends
- Dividend yield
- 0.23%
- Forward dividend
- -
- Payout ratio
- 38.2%
- Ex-dividend date
- Mar 10, 2015
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 7.27M | 0.02 | 38.2% |
| 2024 | CNY 7.19M | 0.02 | - |
| 2023 | CNY 8.69M | 0.02 | - |
| 2022 | CNY 11.1M | 0.02 | 123.5% |
| 2021 | CNY 9.10M | 0.02 | - |
| 2020 | CNY 9.76M | 0.02 | - |
| 2019 | CNY 10.1M | 0.02 | 40.8% |
| 2018 | CNY 16.7M | 0.04 | - |
| 2017 | CNY 7.51M | 0.02 | 118.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Mar 10, 2015.
Who owns Hainan Shuangcheng Pharmaceut
- Insiders 53.29%
- Institutions 0.09%
- Public & others 46.62%
- Shares outstanding 415M
- Free float 208M
Hainan Shuangcheng Pharmaceut company profile
- Company name
- Hainan Shuangcheng Pharmaceut
- Ticker
- 002693.SHE
- ISIN
- CNE100001K63
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 8, 2012
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 448
- Fiscal year end
- December
- Address
- No. 16 Xingguo Road, Haikou, China, 570314
- Phone
- 86 898 6855 7717
- Website
- shuangchengmed.com
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pregabalin capsule; and Memantine Hydrochloride tablets and Pioglitazone tablets USP. Hainan Shuangcheng Pharmaceuticals Co., Ltd. was founded in 2000 and is headquartered in Haikou, the People's Republic of China.
Hainan Shuangcheng Pharmaceut management
10- Mr. Jianming LiGM & Employee Representative Director · born 1956
- Mr. Xuguang WangFinancial Director & Chief Financial Officer · born 1968
- Ms. Xiaofeng YuDeputy GM & Secretary of the Board · born 1974
- Mr. Jianlin YuanDeputy General Manager · born 1973
- Mr. Zhong YaoDeputy General Manager · born 1979
- Mr. Shiying WangDeputy General Manager · born 1981
- Mr. Yixiang AiDeputy General Manager · born 1977
- Ms. Haiyan LiDeputy General Manager · born 1980
- Ms. Rui WangDeputy General Manager · born 1985
- Ms. Yuan LiDeputy General Manager · born 1983